Skip to main content
. 2022 Feb 19;298(4):101748. doi: 10.1016/j.jbc.2022.101748

Figure 2.

Figure 2

Pharmacological inhibition of the TGF-β receptor reduces the adipose tissue level.A and B, gene expression of TGFBR1 and TGFBR2 in human and mouse tissues (human GTEx and mouse ENCODE transcriptomes). C and D, body and tissue weights of C57BL/6J mice 24 h after injection of TGFBR inhibitor (SB431542: 100 mg/kg BW) (n = 6). E, representative image of mouse adipose tissue 24 h after injection of SB431542. F and G, representative confocal image and cell size of visceral adipose tissue 24 h after injection of SB431542. H, representative image of the liver 24 h after injection of SB431542. I, triglyceride content of the liver 24 h after injection of SB431542 (n = 6). J, relative gene expression in visceral adipose tissues of mice injected with SB431542 (n = 6). K, relative gene expression in subcutaneous adipose tissues of mice injected with SB431542 (n = 6). L and M, heatmap of ECM remodeling and lipogenesis-related genes in visceral adipose tissue of SMAD3 knockout mice (GDS3985). N and O, heatmap of ECM remodeling and lipogenesis-related genes in visceral adipose tissue of the mice injected with TGF-β inhibitory antibody (GDS3985). Data are presented as the mean ± SEM. #p < 0.1, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. BW, bodyweight; ECM, extracellular matrix; GTEx, genotype-tissue expression; SMAD3, SMAD family member 3; Sub- or SAT, subcutaneous white adipose tissue (inguinal WAT); TG, triglyceride; TGF-β, transforming growth factor β; TGFBR1, transforming growth factor β receptor type 1; TGFBR2, transforming growth factor β receptor type 2; Vis- or VAT, visceral white adipose tissue (gonadal WAT).